Cell culture-based influenza vaccines: A necessary and indispensable investment for the future

Hemagglutination inhibiting antibodies and protection against seasonal and pandemic influenza infection

(2015) Annette Fox et al.   JOURNAL OF INFECTION

The avian cell line AGE1.CR.pIX characterized by metabolic flux analysis

(2014) Verena Lohr et al.   BMC BIOTECHNOLOGY

Annual public health and economic benefits of seasonal influenza vaccination: a European estimate

(2014) Emmanuelle Preaud et al.   BMC PUBLIC HEALTH

Peering into the Crystal Ball: Influenza Pandemics and Vaccine Efficacy

(2014) Matthew S. Miller et al.   CELL

Characterization of pandemic influenza immune memory signature after vaccination or infection

(2014) Olivia Bonduelle et al.   JOURNAL OF CLINICAL INVESTIGATION

Distinct Cross-reactive B-Cell Responses to Live Attenuated and Inactivated Influenza Vaccines

(2014) Sanae Sasaki et al.   JOURNAL OF INFECTIOUS DISEASES

Assessment of Human Immune Responses to H7 Avian Influenza Virus of Pandemic Potential: Results from a Placebo–Controlled, Randomized Double–Blind Phase I Study of Live Attenuated H7N3 Influenza Vaccine

(2014) Larisa Rudenko et al.   PLoS One

Vaccines, new opportunities for a new society

(2014) R. Rappuoli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Development and preclinical testing of HNVAC, a cell culture-based H1N1 pandemic influenza vaccine from India

(2014) Nagendra R. Hegde et al.   VACCINE

Evaluation of safety and immunogenicity of HNVAC, an MDCK-based H1N1 pandemic influenza vaccine, in Phase I single centre and Phase II/III multi-centre, double-blind, randomized, placebo-controlled, parallel assignment studies

(2014) V.H. Basavaraj et al.   VACCINE

Safety and immunogenicity in man of a cell culture derived trivalent live attenuated seasonal influenza vaccine: A Phase I dose escalating study in healthy volunteers

(2014) Jacco Heldens et al.   VACCINE

Performance characteristics of qualified cell lines for isolation and propagation of influenza viruses for vaccine manufacturing

(2014) Ruben O. Donis et al.   VACCINE

High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells

(2014) Yvonne Genzel et al.   VACCINE

A dose-ranging study of MF59®-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination

(2014) Keith S Reisinger et al.   Human Vaccines & Immunotherapeutics

Immunological assessment of influenza vaccines and immune correlates of protection

(2013) Adrian Reber et al.   Expert Review of Vaccines

Nucleoprotein of influenza A virus is a major target of immunodominant CD8+ T-cell responses

(2013) Emma Grant et al.   IMMUNOLOGY AND CELL BIOLOGY

Safety and Immunogenicity of a Vero Cell Culture-Derived Whole-Virus Influenza A(H5N1) Vaccine in a Pediatric Population

(2013) M. V. W. van der Velden et al.   JOURNAL OF INFECTIOUS DISEASES

Comparison of initial feasibility of host cell lines for viral vaccine production

(2013) Danielle H.W. Vlecken et al.   JOURNAL OF VIROLOGICAL METHODS

Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis

(2013) Harish Nair et al.   LANCET

Cellular immune correlates of protection against symptomatic pandemic influenza

(2013) Saranya Sridhar et al.   NATURE MEDICINE

Clinical Trial to Evaluate the Safety and Immunogenicity of a Trivalent Surface Antigen Seasonal Influenza Vaccine Produced in Mammalian Cell Culture and Administered to Young and Elderly Adults with and without A(H1N1) Pre-Vaccination

(2013) Micha Loebermann et al.   PLoS One

Vaccine-Induced Boosting of Influenza Virus-Specific CD4 T Cells in Younger and Aged Humans

(2013) Douglas V. Dolfi et al.   PLoS One

Comparison of Mutation Patterns in Full-Genome A/H3N2 Influenza Sequences Obtained Directly from Clinical Samples and the Same Samples after a Single MDCK Passage

(2013) Hong Kai Lee et al.   PLoS One

Production of high-titer human influenza A virus with adherent and suspension MDCK cells cultured in a single-use hollow fiber bioreactor

(2013) Felipe Tapia et al.   VACCINE

Correlates of protection to influenza virus, where do we go from here?

(2013) Rebecca Cox   Human Vaccines & Immunotherapeutics

Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies

(2013) Mark Jit et al.   Human Vaccines & Immunotherapeutics

Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®)

(2013) Christof David Vinnemeier et al.   Human Vaccines & Immunotherapeutics

Production of influenza H1N1 vaccine from MDCK cells using a novel disposable packed-bed bioreactor

(2012) Bo Sun et al.   APPLIED MICROBIOLOGY AND BIOTECHNOLOGY

High-yield production of a stable Vero cell-based vaccine candidate against the highly pathogenic avian influenza virus H5N1

(2012) Fangye Zhou et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Evaluation of tumorigenic potential of high yielding cloned MDCK cells for live-attenuated influenza vaccine using in vitro growth characteristics, metastatic gene expression and in vivo nude mice model

(2012) Ramarao S. Vepachedu et al.   BIOLOGICALS

Live attenuated influenza viruses produced in a suspension process with avian AGE1.CR.pIX cells

(2012) Verena Lohr et al.   BMC BIOTECHNOLOGY

Evaluation of Influenza Virus A/H3N2 and B Vaccines on the Basis of Cross-Reactivity of Postvaccination Human Serum Antibodies against Influenza Viruses A/H3N2 and B Isolated in MDCK Cells and Embryonated Hen Eggs

(2012) Noriko Kishida et al.   Clinical and Vaccine Immunology

A Cell Culture-Derived Influenza Vaccine Provides Consistent Protection Against Infection and Reduces the Duration and Severity of Disease in Infected Individuals

(2012) H. J. Ehrlich et al.   CLINICAL INFECTIOUS DISEASES

Comparison of neutralizing antibody and cell-mediated immune responses to pandemic H1N1 2009 influenza virus before and after H1N1 2009 influenza vaccination of elderly subjects and healthcare workers

(2012) J.P. Hsu et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Toward Animal Cell Culture-Based Influenza Vaccine Design: Viral Hemagglutinin N-Glycosylation Markedly Impacts Immunogenicity

(2012) J. Hutter et al.   JOURNAL OF IMMUNOLOGY

CD4+ T-Cell Expansion Predicts Neutralizing Antibody Responses to Monovalent, Inactivated 2009 Pandemic Influenza A(H1N1) Virus Subtype H1N1 Vaccine

(2012) Jennifer L. Nayak et al.   JOURNAL OF INFECTIOUS DISEASES

T-Helper 1 Cells Elicited by H5N1 Vaccination Predict Seroprotection

(2012) Gabriel K. Pedersen et al.   JOURNAL OF INFECTIOUS DISEASES

The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: A Phase I trial in Taiwan

(2012) Sung-Ching Pan et al.   JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION

Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans

(2012) Tom M Wilkinson et al.   NATURE MEDICINE

Immunogenicity, Safety and Reactogenicity of a Mammalian Cell-Culture–Derived Influenza Vaccine in Healthy Children and Adolescents Three to Seventeen Years of Age

(2012) Timo Vesikari et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Comparison of Different Cell Substrates on the Measurement of Human Influenza Virus Neutralizing Antibodies

(2012) Weiguo Zhai et al.   PLoS One

Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine

(2012) Hartmut J. Ehrlich et al.   VACCINE

Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects

(2012) Hiroyuki Fukase et al.   VACCINE

Regulatory, biosafety and safety challenges for novel cells as substrates for human vaccines

(2012) Ralf D. Hess et al.   VACCINE

A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memory

(2012) Alexandra Loew-Baselli et al.   VACCINE

A prospective observational safety study on MF59® adjuvanted cell culture-derived vaccine, Celtura® during the A/H1N1 (2009) influenza pandemic

(2012) Humberto Reynales et al.   VACCINE

A randomized clinical trial to identify the optimal antigen and MF59® adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects

(2012) Christoph Hatz et al.   VACCINE

A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations

(2012) Christoph Hatz et al.   VACCINE

Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: Homologous or heterologous booster response following two dose or single dose priming

(2012) Maikel V.W. van der Velden et al.   VACCINE

In vitro assessment of the allergenicity of novel MF59-adjuvanted pandemic H1N1 influenza vaccine produced in dog kidney cells

(2012) Ramon Bencharitiwong et al.   Human Vaccines & Immunotherapeutics

Economic value of influenza vaccination

(2012) Chiara de Waure et al.   Human Vaccines & Immunotherapeutics

The importance of influenza prevention for public health

(2012) Paloma Carrillo-Santisteve et al.   Human Vaccines & Immunotherapeutics

Trypsin promotes efficient influenza vaccine production in MDCK cells by interfering with the antiviral host response

(2011) Claudius Seitz et al.   APPLIED MICROBIOLOGY AND BIOTECHNOLOGY

Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies

(2011) Sanae Sasaki et al.   JOURNAL OF CLINICAL INVESTIGATION

A Vero Cell–Derived Whole-Virus H5N1 Vaccine Effectively Induces Neuraminidase-Inhibiting Antibodies

(2011) Richard Fritz et al.   JOURNAL OF INFECTIOUS DISEASES

Live and Inactivated Influenza Vaccines Induce Similar Humoral Responses, but Only Live Vaccines Induce Diverse T-Cell Responses in Young Children

(2011) Daniel F. Hoft et al.   JOURNAL OF INFECTIOUS DISEASES

Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial

(2011) P Noel Barrett et al.   LANCET

H5N1 Whole-Virus Vaccine Induces Neutralizing Antibodies in Humans Which Are Protective in a Mouse Passive Transfer Model

(2011) M. Keith Howard et al.   PLoS One

Adaptation of High-Growth Influenza H5N1 Vaccine Virus in Vero Cells: Implications for Pandemic Preparedness

(2011) Yu-Fen Tseng et al.   PLoS One

Impact of Host Cell Line Adaptation on Quasispecies Composition and Glycosylation of Influenza A Virus Hemagglutinin

(2011) Jana Verena Roedig et al.   PLoS One

Immortalized chick embryo cell line adapted to serum-free growth conditions and capable of replicating human and reassortant H5N1 influenza strains for vaccine production

(2011) Paul M. Coussens et al.   VACCINE

Efficient influenza B virus propagation due to deficient interferon-induced antiviral activity in MDCK cells

(2011) Timo Frensing et al.   VACCINE

Plaque purification as a method to mitigate the risk of adventitious-agent contamination in influenza vaccine virus seeds

(2011) Haruhiko Murata et al.   VACCINE

Clinical development of a Vero cell culture-derived seasonal influenza vaccine

(2011) Hartmut J. Ehrlich et al.   VACCINE

Isolation of influenza viruses in MDCK 33016PF cells and clearance of contaminating respiratory viruses

(2011) Bernhard Roth et al.   VACCINE

Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine

(2011) Paul A. Tambyah et al.   VACCINE

Higher titers of some H5N1 and recent human H1N1 and H3N2 influenza viruses in Mv1 Lu vs. MDCK cells

(2011) Sara B Hamilton et al.   Virology Journal

Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children

(2010) Yuji Yasuda et al.   ADVANCES IN THERAPY

In vitro assessment of the allergenicity of a novel influenza vaccine produced in dog kidney cells in individuals with dog allergy

(2010) Niya Wanich et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

MDCK and Vero cells for influenza virus vaccine production: a one-to-one comparison up to lab-scale bioreactor cultivation

(2010) Yvonne Genzel et al.   APPLIED MICROBIOLOGY AND BIOTECHNOLOGY

Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine

(2010) David Onions et al.   BIOLOGICALS

Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process

(2010) Meena George et al.   BIOTECHNOLOGY AND BIOENGINEERING

Pandemic Influenza’s 500th Anniversary

(2010) David M. Morens et al.   CLINICAL INFECTIOUS DISEASES

Clinical Efficacy of Cell Culture–Derived and Egg‐Derived Inactivated Subunit Influenza Vaccines in Healthy Adults

(2010) Sharon Frey et al.   CLINICAL INFECTIOUS DISEASES

Reverse genetic platform for inactivated and live-attenuated influenza vaccine

(2010) Eun-Ju Jung et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

High yields of influenza A virus in Madin-Darby canine kidney cells are promoted by an insufficient interferon-induced antiviral state

(2010) C. Seitz et al.   JOURNAL OF GENERAL VIROLOGY

Adaptation of a Madin–Darby canine kidney cell line to suspension growth in serum-free media and comparison of its ability to produce avian influenza virus to Vero and BHK21 cell lines

(2010) R. van Wielink et al.   JOURNAL OF VIROLOGICAL METHODS

A Whole Virus Pandemic Influenza H1N1 Vaccine Is Highly Immunogenic and Protective in Active Immunization and Passive Protection Mouse Models

(2010) Otfried Kistner et al.   PLoS One

Rapid generation of a well-matched vaccine seed from a modern influenza A virus primary isolate without recourse to eggs

(2010) L.C.S. Hartgroves et al.   VACCINE

Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturing

(2010) Audrey Le Ru et al.   VACCINE

Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans

(2010) Brian A. Crowe et al.   VACCINE

Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: In vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells

(2010) Althaf I. Hussain et al.   VACCINE

A new MDCK suspension line cultivated in a fully defined medium in stirred-tank and wave bioreactor

(2010) V. Lohr et al.   VACCINE

Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines

(2009) P Noel Barrett et al.   Expert Review of Vaccines

Continuous cell lines as a production system for influenza vaccines

(2009) Yvonne Genzel et al.   Expert Review of Vaccines

Genome-wide screening of human T-cell epitopes in influenza A virus reveals a broad spectrum of CD4+ T-cell responses to internal proteins, hemagglutinins, and neuraminidases

(2009) Jenny Aurielle B. Babon et al.   HUMAN IMMUNOLOGY

Safety and Immunogenicity of a Novel Influenza Subunit Vaccine Produced in Mammalian Cell Culture

(2009) Agnieszka Szymczakiewicz‐Multanowska et al.   JOURNAL OF INFECTIOUS DISEASES

Subunit Influenza Vaccines Produced from Cell Culture or in Embryonated Chicken Eggs: Comparison of Safety, Reactogenicity, and Immunogenicity

(2009) Keith S. Reisinger et al.   JOURNAL OF INFECTIOUS DISEASES

A Cell Culture (Vero)–Derived H5N1 Whole‐Virus Vaccine Induces Cross‐Reactive Memory Responses

(2009) Hartmut J. Ehrlich et al.   JOURNAL OF INFECTIOUS DISEASES

Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine

(2009) Tristan W. Clark et al.   NEW ENGLAND JOURNAL OF MEDICINE

Suitability of PER.C6® cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics

(2009) W. Koudstaal et al.   VACCINE

A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine

(2009) Arvydas Ambrozaitis et al.   VACCINE

Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults

(2009) Janet E. McElhaney et al.   VACCINE

Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults

(2009) Wendy A. Keitel et al.   VACCINE

Use of MDCK cells for production of live attenuated influenza vaccine

(2009) Jonathan Liu et al.   VACCINE

Influenza virus CTL epitopes, remarkably conserved and remarkably variable

(2009) Guus F. Rimmelzwaan et al.   VACCINE

A phase I clinical trial of a PER.C6® cell grown influenza H7 virus vaccine

(2009) Rebecca J. Cox et al.   VACCINE

Cloning and assessment of tumorigenicity and oncogenicity of a Madin–Darby canine kidney (MDCK) cell line for influenza vaccine production

(2009) Jonathan Liu et al.   VACCINE

Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines

(2008) M. Keith Howard et al.   BIOLOGICAL CHEMISTRY

Phenotypic Changes in Influenza‐Specific CD8+T Cells after Immunization of Children and Adults with Influenza Vaccines

(2008) Xiao‐Song He et al.   JOURNAL OF INFECTIOUS DISEASES

Capture of cell culture-derived influenza virus by lectins: Strain independent, but host cell dependent

(2008) Lars Opitz et al.   JOURNAL OF VIROLOGICAL METHODS

A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell Culture

(2008) Hartmut J. Ehrlich et al.   NEW ENGLAND JOURNAL OF MEDICINE

A risk-assessment model to rate the occurrence and relevance of adventitious agents in the production of influenza vaccines

(2008) Jens-Peter Gregersen   VACCINE

A quantitative risk assessment of exposure to adventitious agents in a cell culture-derived subunit influenza vaccine

(2008) Jens-Peter Gregersen   VACCINE

Timely production of A/Fujian-like influenza vaccine matching the 2003–2004 epidemic strain may have been possible using Madin–Darby canine kidney cells

(2008) Keiichi Makizumi et al.   VACCINE

Canine MDCK cell lines are refractory to infection with human and mouse prions

(2008) Magdalini Polymenidou et al.   VACCINE

High titer growth of human and avian influenza viruses in an immortalized chick embryo cell line without the need for exogenous proteases

(2008) Kristen A. Smith et al.   VACCINE

An avian cell line designed for production of highly attenuated viruses

(2008) Ingo Jordan et al.   VACCINE

Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: A sequential Phase I and Phase II clinical trial

(2008) N. Groth et al.   VACCINE

Purification and cDNA cloning of a novel protease inhibitor secreted into culture supernatant by MDCK cells

(2007) Kiyoto Nishiyama et al.   BIOLOGICALS